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Background
Hypersensitivity reactions to parenteral administered anti-
biotics (HRPA) are a substantial problem in managing pul-
monary disease in Cystic Fibrosis (CF), especially in
advanced CF. This group of patients requires a life long
antibiotic treatment with extremely high cumulative doses
compared to other patients. In our daily routine we
observed a growing number of hypersensitivities. There-
fore we conducted this observational study to assess
HRPA´s impact on the daily clinical work with CF, as well
as it’s nature, frequency and predisposing risk factors.
Methods
By reviewing medical records and conducting interviews,
age, sex, FEV1, ΔF508-genotype, onset and duration of
pseudomonal colonisation, allergy history (including IgE
serum levels, past ABPA and results of screening tests for
inhalative aeroallergens), parenteral antibiotic exposure
and HRPA (timing, symptoms and treatment) were
recorded. Included were all paediatric and adult patients
at our centre with >3 intravenous antibiotic treatment
courses.
Results
Of 100 patients included in the study, 60 had ≥1 HRPA.
Overall, 3205 antibiotic courses with 185 HRPA were
ascertained. 15% of HRPA met the criteria for anaphylaxis.
Symptoms were mostly dermal (53%). 81% of all and 80%
of anaphylactic HRPA occurred during days 1-4. Approxi-
mately 10% of all treatment courses with cefepime and
piperacillin/tazobactam caused HRPA. The number of
years with pseudomonal colonisation and the cumulative
annual exposure of the given antibiotic were significant
risk factors for HRPA in our patient cohort.
Conclusions
Our results demonstrate that HRPA with a prevalence of
60% are very relevant. During days 1-4 of antibiotic treat-
ment courses patients might be at elevated risk to experi-
ence HRPA. HRPA appear to be drug-specific and to be
dependent on cumulative annual drug exposure of the
given drug. High cumulative dose of the same antibiotic
over a short period of time may lead to a higher risk of
HRPA than the same dose over a longer period of time. Is
this an argument to change the therapeutic regimen more
often? Diagnostic algorithms for this CF-specific problem
should be developed further. Besides recent publications
about drug specific lymphocytes in patients with CF, we
believe that further elucidation of HRPA´s immunological
mechanisms, also concerning immediate reactions and
diagnostics, is needed.
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